192 related articles for article (PubMed ID: 30015608)
1. Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab.
Nolfi-Donegan D; Konar M; Vianzon V; MacNeil J; Cooper J; Lurie P; Sedivy J; Wang X; Granoff DM; McNamara L
Emerg Infect Dis; 2018 Aug; 24(8):1561-4. PubMed ID: 30015608
[TBL] [Abstract][Full Text] [Related]
2. A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab.
Reher D; Fuhrmann V; Kluge S; Nierhaus A
Vaccine; 2018 May; 36(19):2507-2509. PubMed ID: 29631884
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients.
Langereis JD; van den Broek B; Franssen S; Joosten I; Blijlevens NMA; de Jonge MI; Langemeijer S
Blood Adv; 2020 Aug; 4(15):3615-3620. PubMed ID: 32766853
[TBL] [Abstract][Full Text] [Related]
4. Meningococcemia in vaccinated patient under treatment with eculizumab.
Hernando Real S; Vega Castaño S; Pajares García R
Enferm Infecc Microbiol Clin; 2017 Mar; 35(3):200-201. PubMed ID: 26994815
[No Abstract] [Full Text] [Related]
5. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.
McNamara LA; Topaz N; Wang X; Hariri S; Fox L; MacNeil JR
MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):734-737. PubMed ID: 28704351
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R
Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
Keating GM; Lyseng-Williamson KA; McKeage K
BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
[TBL] [Abstract][Full Text] [Related]
8. [Meningococcemia and meningitis due to Neisseria meningitidis W135 developed in two cases vaccinated with bivalent (A/C) meningococcal vaccine].
Turhan V; Acar A; Kılıç A; Budak S; Oncül O; Haznedaroğlu T; Görenek L
Mikrobiyol Bul; 2010 Jul; 44(3):473-8. PubMed ID: 21063998
[TBL] [Abstract][Full Text] [Related]
9. [Meningococcal sepsis without cerebrospinal fluid abnormalities under treatment with eculizumab].
Jentzsch M; Schwind S; Vucinic V; Wendt S; Stingu CS; Niederwieser D; Weidhase L
Med Klin Intensivmed Notfmed; 2020 May; 115(4):340-342. PubMed ID: 30848313
[TBL] [Abstract][Full Text] [Related]
10. Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010-2016.
Rodrigues CMC; Lucidarme J; Borrow R; Smith A; Cameron JC; Moxon ER; Maiden MCJ
Emerg Infect Dis; 2018 Apr; 24(4):673-682. PubMed ID: 29553330
[TBL] [Abstract][Full Text] [Related]
11. Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives.
Whelan J; Bambini S; Biolchi A; Brunelli B; Robert-Du Ry van Beest Holle M
Expert Rev Vaccines; 2015 May; 14(5):713-36. PubMed ID: 25603916
[TBL] [Abstract][Full Text] [Related]
12. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab.
Alashkar F; Vance C; Herich-Terhürne D; Preising N; Dührsen U; Röth A
Ann Hematol; 2017 Apr; 96(4):589-596. PubMed ID: 28124080
[TBL] [Abstract][Full Text] [Related]
13. Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan.
Tanimoto T; Kusumi E; Hosoda K; Kouno K; Hamaki T; Kami M
Orphanet J Rare Dis; 2014 Apr; 9():48. PubMed ID: 24716834
[TBL] [Abstract][Full Text] [Related]
14. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
Rappuoli R; Pizza M; Masignani V; Vadivelu K
Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
[TBL] [Abstract][Full Text] [Related]
15. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
[No Abstract] [Full Text] [Related]
16. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
Socié G; Caby-Tosi MP; Marantz JL; Cole A; Bedrosian CL; Gasteyger C; Mujeebuddin A; Hillmen P; Vande Walle J; Haller H
Br J Haematol; 2019 Apr; 185(2):297-310. PubMed ID: 30768680
[TBL] [Abstract][Full Text] [Related]
17. Quadrivalent meningococcal conjugate vaccines.
Pace D; Pollard AJ; Messonier NE
Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
[TBL] [Abstract][Full Text] [Related]
19. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.
Zareba KM
Drugs Today (Barc); 2007 Aug; 43(8):539-46. PubMed ID: 17925885
[TBL] [Abstract][Full Text] [Related]
20. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage.
Delbos V; Lemée L; Bénichou J; Berthelot G; Deghmane AE; Leroy JP; Houivet E; Hong E; Taha MK; Caron F;
Vaccine; 2013 Sep; 31(40):4416-20. PubMed ID: 23856330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
